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PERSISTENCE OF ALBUNEX® (ALB) ULTRASOUND CON· [;] 
TRAST AGENT: IN·VITRO STUDY OF THE EFFECTS OF 0372 
PRESSURE AND ACOUSTIC POWER ON PARTICLE SIZE, 
AND THE DURATION OF CONTRAST AND DOPPLER EN· 
HANCEMENT. Robin Shandas, David J. Sahn, Gary 
Bales, Taher Elkadi, Kwong·Kun Yau, Morceza 
Gharib, Univ Calif San Diego, CA. 
LV contrast intensity after intravenous ALB 
injection varies with the cardiac cycle, raising 
questions about the pressure related stability 
of the particle. We explored pressure stability 
and the influence of acoustic power on ALB 
effect in an in-vitro pulsatile model at receiv· 
ing chamber (RC) pressures between 10-160 mmHg. 
Ultrasound imaging was performed at SMHz along 
with 3.5MHz color Doppler at maximal and minimal 
levels of acoustic power output on a VingMed CFM 
scanner. We also studied the effects of static 
RC pressure on particle size and survival using 
a new phase shift laser Doppler device (Dantec). 
An inverse relationship existed between RC mean 
pressure and the duration of both echo and Dop· 
pler enhancement (r-0.95 and r-0.94, respec-
tively). At 40-80 mmHg RC pressures, contrast 
persistence determinations were shorter at the 
higher compared to the lower acoustic power out· 
put (p- <0.05). On laser Doppler study, particle 
size decreased as RC pressure increased prior to 
particle disruption. Higher RC pressures com· 
press the ALB micro particle and decrease its 
half-life. Increased acoustic output may also 
shorten ALB effect. 
The Safety of Sonicated Human Albumin (AJbunex) for Repeated 
Echocardlographic Studies in Experimental Animals. 
Bernard P Geny, Paul 0 Pion, Mark 0 Kittleson, William Bommer. 
Schools of Veterina!Y Medicine and Medicine, UniVersity of 
California, Davis, California 
Albunex (ABx) (sonicated human albumin) (HA) ln HA carrier) 
has been developed to provide an echo contrast agent for 
cardiac output, lntracardiac shunt, and myocardial perfusion 
evaluations In humans. Although studies have evaluated the 
safety of single ABx Injections In animals and humans, relatively 
little data are available for repeated injections. We performed 
ABx injections Initially and at 3 weeks and carrier (HA) Injections 
at 5 to 7 weeks after the Initial exposure In a total of 7 animals (5 
dogs, 2 cats) while monitoring for adverse clinical reactions 
(ACR), mean percentage change In mean pulmonary artery 
pressure (xPA), mean systemic arterial pressure (xAP), cardiac 
output (xCO) and echocardlographlc left ventricular shortening 
fraction (xFS). The results are shown in the table below with the 
number of animals In parentheses. 
Injection #ACR xPA xAP xCO xFS 
ABx ~nltlal) 
ABx (second) 
Albumin 
*p<.05 
0(7) 
death(1) 
agitation(S) 
agltation(2) 
+2.2(S) ·2.7(4) ·1(4) 
+S9(5) -46(4)• -41(4)• 
+ 106(2) ·S7(2) -65(2) 
+1.4(4) 
-37(5) 
-60(2) 
The Initial Injection of ABx was well tolerated without 
significant hemodynamic changes. Repeat Injections after 3 
weeks produced adverse clinical effects and hemodynamic 
alterations. These effects appear to be the result of an allergic 
response to HA. The antigenicity of the sonicated fraction Is 
unknown. We conclude that repeated Injections of ABx In 
animals Qnterspecles) conslstendy caused adverse reactions and 
further studies of repeated lnjuectlons In animals and humans 
Qntra species) may be Indicated to evaluate the safety of this 
new agent 
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Combined Glucose-Albumin Solution is Better Than [;] 
Pure Albumin Solution to Opacify the Left 0374 
Ventricle After ~eripheral Venous Injection. 
Shea L Lin, Shuenn J Ho, Tsui L Hsu, Chen H Chen 
, Shih P Wang, Mau s Chang, Benjamin N Chiang. 
Veterans General Hospital-Taipei, Taiwan, R.O.C. 
The microbubble size of the pure 5% albumin 
(A) solution or a combined solution of A adding 
any one of the 10% , 20%, 25%, 30%, 35%, or 50% 
glucose under microscopy was assessed after 
sonication. The potential for transpulmonary 
passage into the left ventricle(LV) of pure A 
and 5% albumin-50% glucose(A-G) solution were 
also evaluated after peripheral injection in 5 
dogs. A total of 100 injections(Sml each) were 
performed. Contrast echo was judged as 0: no 
contrast; 1: faint contrast partially filling 
the LV; 2:Contrast filling the LV; 3: dense 
contrast fully opacifying the LV. Results: The 
microbubble radius of all combined albumin-
glucose solutions was smaller than that of pure 
A solution (9~2 uml. The A-G solution had the 
smallest microbubble radius (7+1 um) • Definite 
(>grade 2) LV contrast was seen-in 16%(8/50) of 
A- and 100%(50/50) of A-G solution injections. 
The peak videodensity of A and A-G solution in 
LV was 21.7% and 44.5% respectively as bright as 
that in the right ventricle. Thus, the A-G 
solution is superior than pure A in smaller 
microbubble size and effective opacification of 
LV after peripheral venous injection in dogs. 
Contrast Enhanced Color Doppler Imaging of Left G;] 
Heart Chambers - First Clinical Results 0375 
Harald Becher, Kelene von Bibra, Kilian Glanzer, 
Reinhard Schlief, Birgit Aupperle, Hans Vetter 
Med.Poliklinik, Bonn, I.Med.Klinik, TU Munchen 
and Clinical Research, Schering AG, Berlin, FRG 
Previous studies have demonstrated an improved. 
sensitivity of color Oopler (CD) imaging by 
echo enhancing agents. In a first clinical trial 
we evaluated the efficacy of intravenous SH U 
508 in enhancing CD recordings of the left heart. 
20 patients with mitral valve disease or coronary 
artery disease were investigated before and after 
intravenous injections of 10 ml SH U 508 (200 and 
300 mg/ml}. The CD recordings (apical views} were 
analyzed using off line color image processing. 
Images with good delineation of flow signals from 
tissue echos were obtained in 19/20 patients 
after injection of 200 mg/ml SH U 508 and in 17/ 
20 after 300 mg/ml. Maximum d!astol ic flow areas 
in the left atrium (%of the cross section areas) 
increased from f5±18% to 5"5±28%, p<0.01 after 
injection of 200 mg/ml SH U 508. In the left ven-
tricle the areas increased from 29±14% to ~±16%, 
p<0.01. The CD enhancement was observed over a 
period of 5 -16 cycles. 
Conclusion: CD imaging with intravenous SH U 508 
provides improved flow display of the left heart 
without impairement of tissue detection. 
